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ABSTRACT
Objective: Neurodegenerative diseases are a debilitating age-related disorder manifested by memory loss, impaired motor activity, and loss of 
muscle tone due to the accumulation of toxic metabolites in the brain. Despite the knowledge of factors causing neurodegenerative disorders, it 
remains irreversible and incurable. Growing evidence have currently advocated the physiological and pathological contribution of hypoxia-induced 
vascular endothelial growth factor (VEGF) in neuronal loss. The objective of this research report highlights biomolecules mediated targeting of VEGF 
activity based on in silico approaches that could establish a potential therapeutic window for the treatment of different abnormalities associated with 
impaired VEGF.
Results: Three-dimensional structure of VEGF was generated and Ramachandran plot obtained for quality assessment. RAMPAGE displayed 
99.5% of residues in the most favored regions, 0.5% residues in additionally allowed, and no residues in disallowed regions in VEGF, showing that 
stereochemical quality of protein structure is good. Further, initial screenings of the molecules were done based on Lipinski’s rule of five. Finally, we 
have found Naringenin to be most effective among three biomolecules in modulating VEGF activity based on minimum inhibition constant, Ki, and 
highest negative free energy of binding with the maximum interacting surface area during docking studies.
Conclusion: The present study outlines the novel potential of biomolecules in regulating VEGF activity for the treatment of different abnormalities 
associated with impaired VEGF.
Keywords: Hypoxia, Vascular endothelial growth factor, Biomolecules, Active site prediction, Molecular docking.
INTRODUCTION
Neurodegenerative diseases are pathological conditions that have an 
insidious onset and chronic progression. Different models have been 
established to study these diseases to understand their underlying 
mechanisms and to investigate new therapeutic strategies [1]. 
Several downstream signaling molecules are reported to trigger 
under hypoxia. Vascular endothelial growth factor (VEGF) is one of 
them, which is responsible for the formation of new blood vessels 
(angiogenesis) and lead to the supply of nutrients and oxygen for 
normal homeostasis [2]. Moreover, the crucial role of VEGF in the brain 
is not restricted only to controlling vessel growth: But it has direct 
effects on different types of neural cells including neural stem cells. 
Conversely, altered expression of this molecule has been implicated in 
virtually every type of angiogenic disorder, including those associated 
with cancer, ischemia, and inflammation [3]. Moreover, studies have 
also revealed the pathological implication of VEGF in the progression 
of neurodegenerative disorders (NDDs) including, Alzheimer’s 
disease, Huntington disease, and amyotrophic lateral sclerosis. 
Recent genetic studies have revealed that reduced VEGF levels cause 
neurodegeneneration through impairing neural tissue perfusion [4]. 
Importantly, implementation of different biomolecules may helpful in 
regulating the altered levels of VEGF in cells. The growing evidence for 
an etiologic role of VEGF in neurodegeneration provides an underlying 
principle for considering the therapeutic potential of VEGF for NDDs, 
which are mostly not curable. In this framework, we have introduced 
different biomolecules (naringenin, quercetin, and sesamol) for 
targeting VEGF. These biomolecules have chemoprotective, anti-
inflammatory, neuroprotective, and anti-aging property. For this 
purpose, we have performed in silico based structural and functional 
analysis of these molecules for revealing its therapeutic importance 
against neuronal loss through modulating the impaired expression of 
VEGF. The objective of this study is to explore neuroprotective action of 
these biomolecules in regulating the altered level of VEGF to attenuate 
the toxicity associated with toxic proteins in neuronal death.
METHODS
Visualization and quality assessment of three-dimensional (3D)-
structure of VEGF
3D-structure of VEGF (ID: 1QTY) was generated using protein data 
bank (PDB), structural evaluation, and stereochemical analysis 
was performed using RAMPAGE (http://www.mordred.bioc.cam.
ac.uk/~rapper/rampage.php). Errat server was used to find the 
accuracy of the structure and visualization of determined structures 
was performed using University of California, San Francisco Chimera.
Active site prediction
The active sites of VEGF were predicted using the Pock Drug tool (http://
pockdrug.rpbs.univ-paris-diderot.fr/cgi-bin/index.py?page=home). 
The PDB structure of VEGF was uploaded and active sites were predicted 
using f-pocket estimation and setting ligand proximity threshold at 5.5.
Ligand optimization
Reported ligand molecules along with their physical and chemical 
properties were retrieved from PubChem Compound Database (http://
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www.pubchem.ncbi.nlm.nih.gov/). PubChem is a composite database 
that is backed up by three primary databases, i.e., polycarbonate 
compounds (PC) substance, PC compund, and PC BioAssay. PubChem 
provides biological activity and chemical information of small 
molecules. PC substance contains information about the substances; 
PC compound contains information about chemical compounds, and 
PC BioAssay provides information about Bioassays. Three compounds 
(naringenin, quercetin, and sesamol) were selected. SDF files of ligands 
were converted in PDB file with the help of Open Babel tool that could 
be used for docking study. Visualization of molecular structure of 
compounds was done using PyMOL.
Lipinski filter analysis of screened drugs
An online tool Lipinski filter (http://www.scfbio-iitd.res.in/software/
drugdesign/lipinski.jsp) was used to retrieve the information about 
drug-likeness properties of biomolecules with the help of Lipinski 
rule of five. Lipinski rule helps differentiate drug and non-drug such as 
properties of molecules. It is used to identify the possibility of success 
or failure due to drug-likeness for molecules fulfiling with two or more 
of the following rules: (a) Molecular mass should be <500 Da, (b) high 
lipophilicity (expressed as log p<5), (c) <5 hydrogen bond donors, 
(d) <10 hydrogen bond acceptors, and (e) molar refractivity should be 
between 40 and 130.
Preparation of protein and ligand molecules
Preparation of protein involves the addition of polar hydrogen atoms, 
neutralization of charge, and removal of any miscellaneous structures 
from the protein molecule by AUTODOCK 4.2.1 whereas ligand 
preparation involves the neutralization of charge.
Molecular docking studies
Prepared and optimized structures of ligands and protein were 
ultimately used for molecular docking using AUTODOCK 4.2.1 for 
predicting the possible protein-ligand interactions and the results that 
include the understanding of the association that involves H-bonding, 
and hydrophobic interactions were analyzed using LIGPLOT1.4.5, a 
program to generate schematic diagrams of protein-ligand interactions.
RESULTS
3D-structure visualization and quality assessment
3D-structure of VEGF was generated and visualized using UCSF 
Chimera (Fig. 1a). Even though, there were no steric clashes in the 
structure generated, it was assessed for geometric and energy aspects. 
Ramachandran plot was used to check the reliability of predicted 
3D-structure of VEGF. RAMPAGE checks the stereochemical quality 
of a protein structure by analyzing residue-by-residue geometry and 
overall structural geometry. Ramachandran plot was obtained for 
VEGF for quality assessment. RAMPAGE displayed 99.5% of residues in 
the most favored regions, 0.5% residues in additionally allowed, and 
no residues in disallowed regions in VEGF (Fig. 1b). Errat server was 
used to determine the accuracy of the model. Result of Errat showed 
95.694% accurate structure for VEGF.
Active site prediction
Of top 10 pockets, VEGF had best pocket at P4 with a drug ability score 
of 0.95 and 0.01 standard deviation (Table 1). The volume of given 
pocket was 1338.57 cubic angstroms and fourteen residues were 
involved in interaction at this site.
Lipinski filter analysis of screened drugs
Further, the screening of ligand molecules was done on the basis 
of Lipinski’s rule of five. Lipinski filter analysis revealed that all the 
compounds selected possessed drug likeness and can be used for 
docking purposes (Fig. 2).
Molecular docking of VEGF with biomolecules
Biomolecules bound to VEGF at P4 pocket and same residues as 
predicted were involved in the interaction. The estimated free energy 
of binding for VEGF and naringenin was - 7.56 kcal/mol and total 
intermolecular energy was - 9.05 kcal/mol. Similarly, the estimated free 
energy of binding for VEGF and quercetin was - 7.10 kcal/mol and total 
intermolecular energy was - 8.89 kcal/mol. Likewise, the estimated free 
energy of binding for VEGF and sesamol was - 5.09 kcal/mol and total 
intermolecular energy was - 5.39 kcal/mol. Molecular docking pattern 
of VEGF with screened molecules (naringenin, quercetin, and sesamol) 
have been identified and depicted in Fig. 3. On the basis of docking 
analysis, interacting compounds with minimum binding constant and 
highest negative free energy of binding are most effective. Docking 
calculation of VEGF with these molecules has been presented in Table 2.
Binding site of VEGF with selected compounds along with its 
reported Inhibitory active site
Binding site residues of VEGF interacting with naringenin, quercetin, 
and sesamol were found to be the same as the residues involved in their 
respective catalytic sites. Interacting residues of VEGF with naringenin, 
quercetin, and sesamol along with their identified catalytic sites have 
Fig. 2: Differentiation of drugs on the basis of Lipinski rule of five 
by Lipinski filter
Fig. 1: (a) Three-dimensional-structure and (b) Ramachandran 
plot of vascular endothelial growth factor protein
ba
Table 1: Active sites of vascular endothelial growth factor
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been show in Table 3 and their two-dimensional and 3D pattern of 
interaction is presented in Fig. 4.
DISCUSSION
Neurodegeneration is an umbrella term for a range of conditions 
which primarily affect the neurons in the human brain [5]. Despite 
the knowledge of various factors which contribute in the occurrence 
and progression of NDDs, the exact cause and cure remains elusive. 
Abnormal expression of VEGF protein in terminally differentiated 
neurons is a recently known phenomenon which has been shown 
to drive neurodegeneration followed by apoptosis [6]. Free-radical 
injury of microvessels under hypoxia causes neuroinflammation and 
oligemia which thereafter leads to Aβ accumulation through vascular 
damage and the activation of proangiogenic factors including, hypoxia-
inducible factor-1α, and VEGF-1 [7]. Further, invading macrophages 
and monocytes also causes neuronal damage through activation of 
VEGF-1 [8]. Similarly, low VEGF levels not only impair spinal cord 
perfusion and cause chronic ischemia of motoneurons but also deprive 
these cells of vital VEGF-dependent survival and neuroprotective signals. 
Both phenomenons result in progressive degeneration of motoneurons, 
associated with muscle weakness, paralysis, and death [9]. Thus, it 
seems imperative to design therapeutic strategies aimed at attenuating 
the altered level of VEGF to inhibit the cascade of neurodegeneration.
Flavonoids have been advocated to exert human health benefits by 
antioxidant and anti-inflammatory mechanisms [10]. Naringenin 
reportedly prevent oxidative stress and nuclear factor kappa B (NF-κB)-
mediated inflammatory brain damage in the rat model of focal cerebral 
injury. Further, prophylactic treatment with naringenin ameliorated 
functional outcomes and abrogated the ischemic brain injury by 
suppressing NF-κB-mediated neuroinflammation [11]. Similarly, a 
significant raise in neuronal survivability was observed with quercetin 
treatment in rats administered 6-OHDA. Both naringenin and quercetin 
also reversed the effect of hypobaric hypoxia and elicit neuroprotective 
response by reducing VEGF level in the murine model [12]. Further, 
sesamol pre-treatment restored oxidative defense possibly by its free 
radical scavenging lighted the neuroprotective effect of sesamol against 
3-NP-induced neuronal damage [13]. Taken together, all these data 
provide convincing evidence of using VEGF interaction bioflavonoids 
such as naringenin and quercetin in attenuating the level of VEGF and 
in turn, inhibit the cascade of neuronal death.
RAMPAGE displayed 99.5% of residues in the most favored regions, 
0.5% residues in additionally allowed and no residues in disallowed 
regions in VEGF, showing that stereochemical quality of protein 
structure is good. Result of Errat showed 95.694% accurate structure 
for VEGF. Lipinski filter analysis of all the compounds revealed that 
these compounds could act such as a drug and have drug-like property 
as these compounds meet the criteria of Lipinski Rule of five. Finally, 
molecular docking studies indicated that all these compounds can bind 
to and modulate the level of VEGF and possibly, halt or inhibit toxic 
proteins induced neuronal death in NDDs. Docking study revealed that 
all three compounds are interacting at the reported active binding site 
and binding atomic coordination was compared with the template 
complex coordination and found that docked drug coordination was 
similar with the known coordination. Amino acid residues of VEGF 
involved in interaction with naringenin, quercetin, and sesamol were 
found to be the same as the residues involved in binding with earlier 
used inhibitors. These observations clearly indicate that we can 
efficiently determine active site coordinates to investigate the effect of 
inhibitors on the functional active site of protein. In this result, the most 
effective compound was found to be naringenin as showing minimum 
inhibition constant, Ki, and lowest free energy of binding with maximum 
interacting surface area [14-17]. These findings can be further validated 
through in vitro and in vivo studies in neurodegeneration. Overall, 
although further work is required, these studies advocate the pivotal 
role of VEGF in NDDs and provide adequate grounds for estimating the 
potential therapeutic effectiveness of VEGF in their management.
CONCLUSION
The results of our study provide novel potential of biomolecules such 
as naringenin, quercetin, and sesamol in regulating VEGF expression 
in the brain, which has wider implications in the progression as well 
as protection against NDDs. Moreover, of these three biomolecules 
naringenin is showing better interaction with VEGF based on their 
minimum binding constant and highest negative free energy.
Fig. 3: Binding of vascular endothelial growth factor with selected 
compounds


























Naringenin −7.56 1.74 −9.05 −9.03 −0.02 +9.69 +1.19
Quercetin −7.10 6.21 −8.89 −8.73 −0.16 +9.49 +1.79
Sesamol −5.09 186.16 −5.39 −5.33 −0.06 +0.33 +0.30
VEGF: Vascular endothelial growth factor
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Table 3: VEGF known inhibitory site and selected compounds interacting residues
Compounds Interacting residues
Reported active site PHE375, VAL376, ASP377, HIS378, ARG379, VAL381, ALA382, GLY385, GLN387, PRO388, GLN389, GLU390, LEU392, LYS432 and ASN433 of 
chain A. GLN434, MET605, THR606, GLU608, GLN609, LYS610, LYS612, GLU613, and GLU616 of chain B. MET598, HIS601, SER602, MET605, 
THR606, LEU607, GLU608, GNL609, THR611, LYS612, GLU613, ILE614, ASP615 and GLU616 of chain C. ARG594, MET598, HIS601, SER602, 
MET605, THR606, GLN609, LYS612 and GLU613 of chain F. SER241, LYS242, ASP259, ARG260, THR262, GLU263, LEU264, ILE265, GLY266, 
HIS268, PRO269, GLU270, ALA311, LYS312, HIS313, GLY314, GLY315, TYR316, VAL317, TRP318, VAL343, and LEU344 of Chain G
Naringenin MET605, THR606, GLU608, and GLN609 residues of chain C and MET605, THR606, and GLN609 residues of chain F
Quercetin GLN609, LYS612, GLU613, and GLU616 residues of chain C and ARG594, MET598, HIS601, and SER602 residues of chain F
Sesamol MET598, HIS601, and SER602 residues of chain C and GLN609, LYS612, and GLU613 residues of chain F
VEGF: Vascular endothelial growth factor
Fig. 4: Three-dimensional- and two-dimensional-representation 
of vascular endothelial growth factor and ligand interaction
